Earlier this month, Compass Pathways shared topline data from Part C of its smaller, placebo-controlled Phase 3 trial, COMP005. As a reminder, COMP005 enrolled 258 patients with treatment-resistant depression (TRD) to receive either a 25 mg dose of the company’s psilocybin candidate (COMP360) or inert placebo. Participants received their first dose in Part A, a 6-week blinded portion of the…
